SYDNEY – (BUSINESS WIRE) – Australian drug development company Noxopharm Limited (ASX: NOX) in the clinical stage has announced an international patent application to protect the use of the experimental cancer drug Veyonda® (Idronoxil) to block the development of infection-related septic shock such as COVID-19 and influenza viruses.
Overall, septic shock is believed to be responsible for an estimated 10 million deaths worldwide each year, with an estimated three million additional deaths caused by the current pandemic. So-called “long-term COVID” symptoms (e.g. prolonged fatigue, breathing problems, headache) as well as severe organ damage (e.g. limb amputation, diabetes, kidney and heart failure) and death are all results in connection with septic diseases shock .
Veyonda is being developed as a cancer drug based on immune stimulation and anti-inflammatory functions. Its anti-inflammatory effects work by blocking a signaling pathway called STING, which normally acts as a trigger for an inflammatory response to repair damaged tissue such as virally infected lungs. In some people, the STING response is inappropriately high, causing the person to go into septic shock. Veyonda is the first drug to block STING and to be tested in septic shock, including in COVID-19 patients.
Graham Kelly, CEO of Noxopharm, said: “Globally, someone dies of septic shock every three seconds, as often as cancer. Inexpensive treatment for septic shock doubles the commercial options for Veyonda. ”
Noxopharm Limited (ASX: NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock.
Veyonda® is the company’s first pipe-line drug candidate currently in Phase 2 clinical trials. Veyonda® has two main drug effects – a moderating effect on the ceramide / sphingosine-1-phosphate balance and the inhibition of STING signal transmission. Activity against the former contributes to its dual acting oncotoxic and immuno-oncological functions, which are designed to improve the effectiveness and safety of standard oncological treatments, ie chemotherapy, radiation therapy and immune checkpoint inhibitors. The activity against the latter target causes an anti-inflammatory effect, which also contributes to an anti-cancer effect, but possibly also blocks the septic shock.